Business Wire

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Jaa

Boehringer Ingelheim today announced that Phase II results from LUME-Meso, a randomised, double-blind, placebo-controlled trial, have been presented as part of an Oral Abstract Session at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO). Nintedanib*, an oral triple angiokinase inhibitor, demonstrated improved progression-free survival (PFS, primary endpoint) and overall survival (OS, secondary endpoint) when added to standard first-line chemotherapy of pemetrexed/cisplatin in patients with malignant pleural mesothelioma (MPM) compared to chemotherapy alone. In this study, treatment with nintedanib or placebo continued after chemotherapy until progression or toxicity.

MPM is a rare thoracic cancer, representing less than 1% of all cancers and is often related to long-term asbestos exposure. MPM patients have a poor prognosis, with less than 10% surviving for five years following diagnosis. MPM is broadly categorised by cell type, or histology, in three subtypes (epithelioid, biphasic and sarcomatoid) with epithelioid being the most common, accounting for 50%-70% of all diagnoses.

The updated Phase II PFS results from the LUME-Meso study showed oral, twice-daily nintedanib, when added to standard chemotherapy, nearly halved the risk of disease progression. A 46% reduction was demonstrated, with a significant improvement in median PFS of 3.7 months (9.4 nintedanib vs 5.7 placebo) in the overall study population (patients with either an epithelioid or biphasic cell type) compared to placebo plus standard chemotherapy alone. In patients with an epithelioid cell type, nintedanib plus chemotherapy demonstrated a greater median PFS benefit of 4 months (9.7 nintedanib vs 5.7 placebo).

The primary OS analysis showed an encouraging 4.1 month improvement in the median OS for patients receiving nintedanib in addition to chemotherapy (18.3 nintedanib vs 14.2 placebo), demonstrating a positive trend in the overall population, without reaching significance. Similarly to PFS, the effect was the greatest in patients with epithelioid histology, whose median overall survival was 20.6 months compared to 15.2 months with chemotherapy alone.

The safety profile of the experimental combination with nintedanib was as expected. Neutropenia (an abnormally low level of neutrophils, a type of white blood cell) was the most frequent grade ≥3 adverse event (nintedanib 43.2% vs placebo 12.2%); rates of febrile neutropenia were low (2.3% vs 0%). AEs leading to discontinuation were low, with fewer patients discontinuing treatment with nintedanib than in those patients in the placebo plus chemotherapy arm (3 patients vs. 7 patients; 6.8% vs 17.1%). Typical AEs observed with anti-angiogenesis compounds (e.g. hypertension, bleeding, thromboembolic event) were seen infrequently.

Dr. Mehdi Shahidi, Corporate Vice President and Global Head of Oncology, Medicine at Boehringer Ingelheim commented, “We are pleased to see that the addition of nintedanib to standard first-line chemotherapy may translate into meaningful improvements in patients’ outcomes. MPM is a difficult-to-treat disease and these data are another encouraging step on our way to fulfilling the commitment of Boehringer Ingelheim to deliver novel therapeutic options to patients with malignant diseases.”

Nintedanib is currently being studied in the LUME-Meso Phase III trial [NCT01907100] and is recruiting at trial sites worldwide. Nintedanib targets the receptors of the VEGF, FGF, PGF and Src and Abl signaling, which are implicated in the development of malignant pleural mesothelioma.

*Nintedanib is approved in the EU and more than 20 other countries worldwide under the brand name VARGATEF ® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer of adenocarcinoma tumour histology after first-line chemotherapy. Nintedanib is not approved in other oncology indications.

Intended audiences
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit: https://www.boehringer-ingelheim.com/press-release/mesothelioma-phase-ii

For more information, please visit: www.boehringer-ingelheim.com

Further media channels
www.facebook.com/boehringeringelheim
www.twitter.com/Boehringer
www.youtube.com/user/boehringeringelheim

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Julia Knebel
55216 Ingelheim/Germany
Phone +49 (6132) 77-95614
Fax +49 6132 77 6601
Email: press@boehringer-ingelheim.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

UL Joins Sustainable Apparel Coalition19.10.2017 15:00Tiedote

UL announces that it has joined the Sustainable Apparel Coalition (SAC) and will use the group’s sustainability measurement tool, the Higg Index, to drive environmental and social responsibility throughout its supply chain. With its membership in the SAC, UL joins more than 200 global brands, retailers and manufacturers, as well as government, non-profit environmental organizations, and academic institutions, which are collectively committed to improving supply chain sustainability in the apparel, footwear and textile industries. UL partners with clients to support them with every aspect of sustainability and supply chain management, including developing a proactive stance and demonstrating ‘green’ and sustainable credentials, assist in gaining better visibility into supply chain issues and mitigate risk and implementing customized and comprehensive Environmental Mana

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting19.10.2017 14:30Tiedote

Celgene Corporation (NASDAQ:CELG) today announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, in relapsing multiple sclerosis (RMS) were accepted for the MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting, which is being held in Paris, October 25-28, 2017. “Our strong presence at this year’s meeting and the breadth of data being presented on ozanimod highlight our commitment to bringing forth ozanimod as a potential novel, oral therapeutic option for people with multiple sclerosis,” said Terrie Curran, President, Celgene Inflammation and Immunology. Full results from the phase III SUNBEAM™ and RADIANCE™ Part B studies evaluating two doses of oral ozanimod compared with Avonex® (interferon beta-1a) (IFN) in people with RMS will be presented as an oral and a late-break

Exclusive Group Adds Mellanox to BigTec Portfolio19.10.2017 11:00Tiedote

Exclusive Group, the value-added services and technologies (VAST) group, today announced it has struck a major distribution agreement with Mellanox Technologies to add the market-leading vendor’s datacentre interconnect solutions to the global BigTec portfolio. The deal, which sees Mellanox and BigTec team up in 24 countries across EMEA and APAC, brings global expansion opportunities to both parties as well as hundreds of reseller partners, providing the ideal complement to storage and hyper-converged solutions from fellow BigTec vendors including Nutanix and Rubrik. “Mellanox has a unique and comprehensive technology offering that reflects both its commitment to open standards in networking and cloud computing, and its hunger to continually disrupt the datacentre market,” said Martin Bichler, Group Vendor Manager, BigTec. “This is yet another bonus for BigTec specialist resellers and

More Firms Select Duco for Mandatory MiFID II Reconciliation19.10.2017 10:01Tiedote

Duco, the global provider of self-service data normalization and reconciliation services, today announced that a further three firms will be using Duco Cube, the company’s flagship reconciliation solution, for MiFID II reporting reconciliation. The firms include Redburn, Europe’s largest independent equities broker, and two global banks. Ranith de Silva, Operations Manager at Redburn, said: “MiFID II transaction data needs to undergo a number of enrichment processes between front office capture and the final report, which need to be replicated in the reconciliation process, covering large complex data sets. The quick deployment, flexibility and usability of Duco's self-service application enables us to efficiently build towards this reconciliation process with very little technical support.” Regular reconciliation is a mandatory requirement under MiFID II. The firms w

SIAE MICROELETTRONICA Successfully Tests The SDN Application iVeritas in Telefónica Deutschland’s SDN Live Wireless Network19.10.2017 10:00Tiedote

SIAE MICROELETTRONICA announces the successful deployment of iVeritas in Telefónica Deutschland's mobile backhaul as part of the TST project. Telefónica Deutschland Transport SDN Trial (TST), is a project whose long-term aim is offering value added services on future 5G network infrastructure in an SDN environment. As part of this project SIAE MICROELETTRONICA, a Telefónica long term supplier of wireless technology, deployed its new SDN application named iVeritas offering multivendor performance analytics and preventive maintenance analysis. iVeritas sits on top of the OpenDaylight transport SDN controller that through an SDN mediator interfaces to existing SNMP microwave links, the selected portion of the network was composed by links from three different vendors. iVeritas collected performance information from the links, correlating the data and presenting them acco

Rimini Street Expands Investment and Operations in Europe19.10.2017 01:00Tiedote

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of industry leader Marc Chesover as general manager of Europe, the Middle East and Africa (EMEA). The Company also announced the launch of its French subsidiary, hiring of new staff and opening of its new office in Paris, France. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006654/en/ Rimini Street Expands Investment and Operations in Europe (Photo: Business Wire) Enterprise Software Veteran Leads EMEA Operations Rimini Street’s new general manager, Marc Chesover, will lead the Company’s sales and service delivery operations across EMEA, and the next p

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme